Millipore Sigma Vibrant Logo

IM13L Anti-uPA (Ab-1) Mouse mAb (5)

This Anti-uPA (Ab-1) Mouse mAb (5) is validated for use in Frozen Sections, Immunoblotting, Immunoprecipitation, Paraffin Sections for the detection of uPA (Ab-1).

Anti-uPA (Ab-1) Mouse mAb (5) : FDS (Fiches de données de sécurité), certificats d’analyse (CoA) et de qualité (CoQ), dossiers, brochures et autres documents disponibles.
IM13L
  
Prix en cours de récupération
Le prix n'a pas pu être récupéré
La quantité minimale doit être un multiple de
Maximum Quantity is
À la validation de la commande Plus d'informations
Vous avez sauvegardé ()
 
—
Demander le prix
—
Disponibilité limitée Disponibilité limitée
En stock 
Interrompu(e)
Disponible en quantités limitées
Disponibilité à confirmer
    Pour le restant : Nous vous tiendrons informé
      Pour le restant : Nous vous tiendrons informé
      Nous vous tiendrons informé
      Contacter le Service Clients
      Contact Customer Service

       

      Contacter le Service Clients

      Aperçu

      Replacement Information

      Tableau de caractéristiques principal

      Host
      M
      Description
      OverviewRecognizes uPA/PAI complexes and receptor-bound uPA in HT-1080 cells or carcinoma tissue. Sold under license of U.S. Patent 5,422,245.

      This product has been discontinued.
      Catalogue NumberIM13L
      Brand Family Calbiochem®
      References
      ReferencesFoekens, J. A., et al. 1992. Cancer Res. 52, 6101.
      Andreasen, P. A., et al. 1990. Mol. Cell. Endocrinol. 68, 1.
      Blasi, F. and Verde, P., 1990. in Seminars in Cancer Biology, ed. M. M. Gottesman. Vol. 1, 153.
      Duffy, M. J., et al. 1990. Cancer Res. 50, 6827.
      Jänicke, F., et al. 1990. Fibrinolysis 4, 69.
      Blasi, F., et al. 1987. J. Cell Biol. 104, 801.
      Nielsen, L. S., et al. 1986. J. Immunoassay. 7, 209.
      Product Information
      DeclarationSold under license of U.S. Patent 5,422,245.
      FormLyophilized
      FormulationLyophilized from a volatile buffer, 100 µg of BSA.
      Positive controlConcentrated conditioned medium from HT-1080 cells or carcinoma tissue
      PreservativeNone
      Applications
      Application ReferencesImmunoprecipitation Nielsen, L. S., et al. 1986. J. Immunoassay. 7, 209. Immunoblotting Nielsen, L. S., et al. 1986. J. Immunoassay. 7, 209.
      Key Applications Frozen Sections
      Immunoblotting (Western Blotting)
      Immunoprecipitation
      Paraffin Sections
      Application NotesFrozen Sections (10 µg/ml)
      Immunoblotting (1 µg/ml, see application references)
      Immunoprecipitation (1 µg, see application references)
      Paraffin Sections (20-50 µ/ml; heat pre-treatment required, see comments)
      Application CommentsRecognizes uPA when it is complexed with PAI-1 or the uPA receptor. For optimal results in immunoblotting, concentration of the HT1080 media 10-20x is recommended. For paraffin sections, pretreat by boiling in 6 M urea for 15 min, then incubate overnight with 20-50 µg/ml antibody at 37°C. Antibody should be titrated for optimal results in individual systems.
      Biological Information
      Immunogenhuman urine urokinase plasminogen activator
      ImmunogenHuman
      Clone5
      HostMouse
      IsotypeIgG₁
      Physicochemical Information
      Dimensions
      Materials Information
      Toxicological Information
      Safety Information according to GHS
      Safety Information
      Product Usage Statements
      Storage and Shipping Information
      Ship Code Ambient Temperature Only
      Toxicity Standard Handling
      Storage +2°C to +8°C
      Do not freeze Ok to freeze
      Special InstructionsWe recommend resuspending the lyophilized antibody with sterile phosphate buffered saline (PBS), pH 7.4, or sterile 20 mM Tris-saline (20 mM Tris containing 0.15 M NaCl), pH 7.4, to yield a final concentration of 100 μg/ml. Lyophilized antibodies should be resuspended at 4°C with occasional gentle mixing for at least 2 h. Following reconstitution, aliquot and freeze (-20°C) for long-term storage or refrigerate (4°C) with 0.1% azide for short-term storage. Avoid freeze/thaw cycles.
      Packaging Information
      Transport Information
      Supplemental Information
      Specifications
      Global Trade Item Number
      Référence GTIN
      IM13L 0

      Documentation

      Anti-uPA (Ab-1) Mouse mAb (5) FDS

      Titre

      Fiche de données de sécurité des matériaux (FDS) 

      Anti-uPA (Ab-1) Mouse mAb (5) Certificats d'analyse

      TitreNuméro de lot
      IM13L

      Références bibliographiques

      Aperçu de la référence bibliographique
      Foekens, J. A., et al. 1992. Cancer Res. 52, 6101.
      Andreasen, P. A., et al. 1990. Mol. Cell. Endocrinol. 68, 1.
      Blasi, F. and Verde, P., 1990. in Seminars in Cancer Biology, ed. M. M. Gottesman. Vol. 1, 153.
      Duffy, M. J., et al. 1990. Cancer Res. 50, 6827.
      Jänicke, F., et al. 1990. Fibrinolysis 4, 69.
      Blasi, F., et al. 1987. J. Cell Biol. 104, 801.
      Nielsen, L. S., et al. 1986. J. Immunoassay. 7, 209.
      Fiche technique

      Note that this data sheet is not lot-specific and is representative of the current specifications for this product. Please consult the vial label and the certificate of analysis for information on specific lots. Also note that shipping conditions may differ from storage conditions.

      Revision27-August-2007 RFH
      ApplicationFrozen Sections (10 µg/ml)
      Immunoblotting (1 µg/ml, see application references)
      Immunoprecipitation (1 µg, see application references)
      Paraffin Sections (20-50 µ/ml; heat pre-treatment required, see comments)
      DescriptionPurified mouse monoclonal antibody generated by immunizing BALB/c mice with the specified immunogen and fusing splenocytes with NS-1 mouse myeloma cells. Recognizes uPA/PAI complexes and receptor-bound uPA.
      BackgroundUrokinase-type plasminogen activator (uPA) is a serine proteinase that functions in the conversion of plasminogen to the active proteinase, plasmin1. It is secreted from cells as an inactive 52 kDa precursor (single-chain or sc-uPA) which is activated to the two-chain form consisting of an A and B-chain. The active high molecular weight form (HMW-uPA) can be further processed by removal of an amino-terminal fragment (ATF) to an active low molecular weight form (LMW-uPA) of 33 kDa. The B-chain contains the active site and binds the two endogenous plasminogen activator inhibitors, PAI-1 and PAI-22. The binding of pro-uPA to its cell surface receptor enhances its rate of activation3. uPA is responsible for normal physiological processes such as tissue remodeling and cell migration. Since cell surface plasminogen activation is involved in extracellular matrix degradation, uPA is likely to play a key role in the process of invasion and metastasis. Several studies indicate that uPA may be a useful prognostic indicator for cancer.
      HostMouse
      Immunogen speciesHuman
      Immunogenhuman urine urokinase plasminogen activator
      Clone5
      IsotypeIgG₁
      Specieshuman
      Positive controlConcentrated conditioned medium from HT-1080 cells or carcinoma tissue
      FormLyophilized
      FormulationLyophilized from a volatile buffer, 100 µg of BSA.
      PreservativeNone
      CommentsRecognizes uPA when it is complexed with PAI-1 or the uPA receptor. For optimal results in immunoblotting, concentration of the HT1080 media 10-20x is recommended. For paraffin sections, pretreat by boiling in 6 M urea for 15 min, then incubate overnight with 20-50 µg/ml antibody at 37°C. Antibody should be titrated for optimal results in individual systems.
      Storage +2°C to +8°C
      Do Not Freeze Ok to freeze
      Special InstructionsWe recommend resuspending the lyophilized antibody with sterile phosphate buffered saline (PBS), pH 7.4, or sterile 20 mM Tris-saline (20 mM Tris containing 0.15 M NaCl), pH 7.4, to yield a final concentration of 100 μg/ml. Lyophilized antibodies should be resuspended at 4°C with occasional gentle mixing for at least 2 h. Following reconstitution, aliquot and freeze (-20°C) for long-term storage or refrigerate (4°C) with 0.1% azide for short-term storage. Avoid freeze/thaw cycles.
      Toxicity Standard Handling
      ReferencesFoekens, J. A., et al. 1992. Cancer Res. 52, 6101.
      Andreasen, P. A., et al. 1990. Mol. Cell. Endocrinol. 68, 1.
      Blasi, F. and Verde, P., 1990. in Seminars in Cancer Biology, ed. M. M. Gottesman. Vol. 1, 153.
      Duffy, M. J., et al. 1990. Cancer Res. 50, 6827.
      Jänicke, F., et al. 1990. Fibrinolysis 4, 69.
      Blasi, F., et al. 1987. J. Cell Biol. 104, 801.
      Nielsen, L. S., et al. 1986. J. Immunoassay. 7, 209.
      Application referencesImmunoprecipitation Nielsen, L. S., et al. 1986. J. Immunoassay. 7, 209. Immunoblotting Nielsen, L. S., et al. 1986. J. Immunoassay. 7, 209.